Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Cambrex Corporation    CBM

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
03/21/2017 03/22/2017 03/23/2017 03/24/2017 03/27/2017 Date
50.25(c) 50.9(c) 50.9(c) 50.45(c) 50.6(c) Last
384 355 247 849 312 598 236 213 180 428 Volume
-1.28% +1.29% 0.00% -0.88% +0.30% Change
More quotes
Financials ($)
Sales 2017 536 M
EBIT 2017 140 M
Net income 2017 95,5 M
Debt 2017 -
Yield 2017 -
Sales 2018 583 M
EBIT 2018 154 M
Net income 2018 103 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 17,83
P/E ratio 2018 16,43
Capi. / Sales2017 3,20x
Capi. / Sales2018 2,94x
Capitalization 1 715 M
More Financials
Company
Cambrex Corp. engages in the provision of products, services, and technologies to accelerate and improve the development and commercialization of new and generic therapeutics.It supplies to innovator and generic pharmaceutical companies.Its products include generic and branded APIs, controlled... 
Sector
Pharmaceuticals
Calendar
05/05Earnings Release
More about the company
Surperformance© ratings of Cambrex Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on CAMBREX CORPORATION
03/23 GLOBAL NICOTINE GUM CONSUMPTION MARK : Reynolds American, Cambrex Corporation, F..
03/03 INSIDER TRADING ACTIVITY CAMBREX COR : CBM) – CEO Sold 12,000 shares of St..
02/28 INSIDER TRADING ACTIVITY CAMBREX COR : CBM) – COO Sold 19,620 shares of St..
02/15 Cambrex to Present at the 2017 RBC Capital Markets Global Healthcare Conferen..
02/08 CAMBREX : riding high on demand for Western innovator APIs
02/03 CAMBREX CORPORATION : (CBM) Jumps on Earnings Estimate
02/03 CAMBREX : Management's Discussion and Analysis of Financial Condition and Result..
02/03 CAMBREX : posts 4Q profit
02/03 CAMBREX CORPORATION (NYSE : CBM) Files An 8-K Results of Operations and Financia..
02/03 CAMBREX CORP : Results of Operations and Financial Condition, Financial Statemen..
More news
Sector news : Pharmaceuticals - NEC
03/27DJALEXION PHARMACEUTICALS : Names New CEO Following Internal Sales-Practice Probe
03/27DJEU Clears Dow-DuPont Deal With Conditions -- 2nd Update
03/27DJEU Clears Dow-DuPont Deal With Conditions -- Update
03/27 Chinese drug approval boosts AstraZeneca's lung cancer hopes
03/24 NOVO NORDISK A/S : EMA panel backs Novo Nordisk's haemophilia B drug
More sector news : Pharmaceuticals - NEC
Latest Tweets
03/22Best Price-Positioned Integrated Oil & Gas Stocks, As Seen By Market-Make.. 
03/11Cambrex Co. $CBM Short Interest Up 50.1% in February  
03/07#EquityResearch Cambrex: An Undervalued Stock $GILD $CBM  
03/07Cambrex: An Undervalued Stock  
03/03Cambrex Corporation $CBM CEO Steven M. Klosk Sells 12,000 Shares of Stock  
More tweets
Qtime:14
News from SeekingAlpha
03/22 Best Price-Positioned Integrated Oil & Gas Stocks, As Seen By Market-Makers
03/07 CAMBREX : An Undervalued Stock
02/22 Cambrex (CBM) Presents at RBC Capital Markets Global Healthcare Conference 20..
02/15 CAMBREX : A Pure Growth Play
02/03 Cambrex's (CBM) CEO Steven Klosk on Q4 2016 Results - Earnings Call Transcrip..
Advertisement
Chart CAMBREX CORPORATION
Duration : Period :
Cambrex Corporation Technical Analysis Chart | CBM | US1320111073 | 4-Traders
Full-screen chart
Technical analysis trends CAMBREX CORPORATION
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 56,8 $
Spread / Average Target 12%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Steven M. Klosk President, Chief Executive Officer & Director
Shlomo Yanai Non-Executive Chairman
Shawn P. Cavanagh Chief Operating Officer & Executive Vice President
Tom Vadaketh Chief Financial Officer & Vice President
Peter G. Tombros Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CAMBREX CORPORATION-6.49%1 715
JOHNSON & JOHNSON8.91%340 163
ROCHE HOLDING LTD.8.73%219 545
PFIZER INC.4.68%202 474
NOVARTIS AG-0.94%195 096
MERCK & CO., INC.7.32%173 465
More Results